Halo Pharma, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Halo Pharma, Inc. - overview
Established
2006
Location
-, NJ, US
Primary Industry
Pharmaceuticals
About
Halo Pharma, Inc. is a Contract Developmen t and Manufacturing Organization (CDMO) specializing in the formulation, development, and manufacture of complex therapeutics for pharmaceutical innovators and generics. Founded in 2006, Halo Pharma, Inc. operates as a CDMO, focusing on complex therapeutic solutions.
In July 2018, Cambrex Corporation acquired Halo Pharma, Inc. from SK Capital Partners for USD 425 million. Halo Pharma provides comprehensive services as a CDMO, including formulation development, clinical supplies, commercial manufacturing, analytical testing, and dosage packaging. Its expertise includes a variety of dosage forms such as solids, liquids, semi-solids, and specialty forms.
The company serves over 85 unique clients in North America and operates facilities compliant with regulations from the FDA, DEA, Health Canada, and the European Medicines Agency. Halo Pharma's revenue is primarily generated through B2B agreements with pharmaceutical companies needing specialized drug development and manufacturing services. The company has successfully supported the production of over 90 commercial products for 30 clients in 2023, utilizing a transaction model that includes milestone payments tied to project deliverables. Following its acquisition by Cambrex Corporation, which is set to close in the third quarter of 2018, Halo Pharma plans to leverage the resources and capabilities of Cambrex to enhance its service offerings and expand into new markets.
The integration aims to improve operational efficiencies and support the introduction of new products in the therapeutic space.
Primary Industry
Pharmaceuticals
Sub Industries
Pharmaceutical Research & Development
Website
www.halopharma.com
Verticals
Manufacturing
Company Stage
Acquired
Total Amount Raised
Subscriber access only
Halo Pharma, Inc. - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Trade Sale | Completed | Halo Pharma, Inc. | - | ||||||||
| Growth | Completed | Halo Pharma, Inc. | - |
Displaying 1 - 2 of 2
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.